Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Bio Q3 Revenues Rise 6 Percent

NEW YORK – Interpace Biosciences reported Wednesday morning that its third quarter revenues rose 6 percent year over year.

For the three months ended Sept. 30, 2020 the Parsippany, New Jersey-based firm had total revenues of $8.2 million compared to $7.7 million a year ago, beating analysts' average expectations of $7.6 million.

Interpace also announced that it closed a $5 million bridge loan with existing equity investors Ampersand Capitol Partners and 1315 Capital Partners earlier this month. The firm concurrently terminated its credit facility with Silicon Valley Bank.

Subsequent to the end of the third quarter, Interpace received notice from the Nasdaq that it was in violation of a Nasdaq Listing rule due to the delay in filing its Form 10-Q for the quarter ended Sept. 30.

Interpace posted a net loss of $6.2 million, or $1.54 per share, compared to a net loss of $7.4 million, or $1.97 per share a year ago. The firm beat the consensus Wall Street estimate of a net loss of $1.92 per share.

The company's R&D expenses fell 11 percent to $763,000 from $857,000 in the year-ago period. It's sales, marketing, general, and administrative expenses fell 1 percent to $7.2 million from $7.3 million.

Interpace finished the quarter with $5.3 million in cash and cash equivalents.

For the fourth quarter, the company estimated revenues to be between $9.0 and $10.0 million.

In early morning trading on the Nasdaq, Interpace's shares were down about 11 percent at $4.06.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.